The role of monocytes in the development of natural immunity to Plasmodium infection
Year: 2016
Type: article
Abstract: Part I: Literature Review Immunity to Malaria and the Role of MonocytesMalaria as a global health problem Malaria, caused by parasites of the genus Plasmodium, is a leading cause of infectious morbidity and mortality worldwide, resulting in an estimated 154-289 million infections and 660,000 deaths in 2010 (WHO Global Malaria Programme, 2012).Of those infected by Plasmodium parasites, children and pregnant women face the highest risks of severe complications and death (Murphy and Breman, 2001).Additionally, of those who experience cerebral malaria, a severe version of malaria characterized by coma and seizures, approximately 15% will experience neurological sequelae, with risks of permanent neurological impairment (van Hensbroek et al., 1997;Mung'ala-Odera et al., 2004).Unsurprisingly considering the incidence and high disease burden, malaria exacts a tremendous economic toll on already economically vulnerable regions (Sachs and Malaney, 2002).Plasmodium falciparum, the major causative agent in human malaria, is estimated to have emerged as a species 100,000 years ago, at the same time as humans, and has been one of the greatest evolutionary pressures on the human immune system (Crompton et al., 2014;Kwiatkowski, 2005).Perhaps due to this coevolution, Plasmodium sp. have been particularly skilled at evading human immunity.Natural immunity against malarial disease is slow to develop and short lived once exposure to Plasmodium is removed (Schofield and Mueller, 2006).As a result, current clinical management relies heavily on pharmacological treatment of malarial disease; however, drug resistant strains of Plasmodium falciparum are on the rise, with drug development struggling to keep up (Kim and Schneider, 2013).An efficacious, long lasting vaccine is highly desirable, but its development has proven difficult (Wykes, 2013).The most clinically advanced vaccine candidate, RTS,S, provides less than 50% protection from malaria disease in children ages 5-17 months old, and has only a 27% efficacy in young infants, the vaccine's initial target population (Agnandji et al., 2014).Furthermore, this protection was greatly diminished by 18 months following vaccination (Agnandji et al., 2014).A better understanding of the mechanisms that promote and hinder the development of natural immunity to malaria could provide vital clues to guide the development of novel therapies and long lasting vaccines. Malaria infection -Plasmodium sp. parasites life cyclePlasmodium falciparum parasites have a complex life cycle that requires both human and Anopholes mosquito hosts.Initial human infection occurs when an infected female mosquito takes a blood meal from a human.Her saliva contains the sporozoite form of P. falciparum, and during the blood meal approximately 10-100 of these sporozoites are injected into the skin.After remaining in the skin for hours to days, the sporozoites migrate through the bloodstream
Author: Alyssa Baccarella
Language: English
Topic: Malaria Research and Control
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2910704220
